Solid Biosciences (SLDB) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.38

Estimate

-$0.47

Surprise

+18.6%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Solid Biosciences (SLDB) reported a narrower loss than forecast — diluted EPS of -$0.38 against the -$0.47 estimate (a 18.6% beat on a still-unprofitable quarter).

TrendMatrix currently rates SLDB Sell at 5.7/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +18.6% surprise compares with a +5.7% four-quarter average. Next scheduled report: 2026-11-02.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$9.30

Price target

$15.34

Stop

$8.65

Upside to target

+64.9%

Reward-to-risk

4.3:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$997.2M

P/E (fwd)

-5.3

52-week range

$3.79–$11.45

Off 52-week high

18.8%

RSI (14)

68

Volume vs avg

0.87×

Score today

5.7/10